Ed Wu

Ed Wu asked if the weather-related supply issues affecting inventory in the channel have been corrected, and if there are any potential issues with ramping up production if demand for EXXUA increases faster than expected.

Answer

CEO Josh Disbrow confirmed that weather-related delays of a few days have been corrected, and supply is currently adequate. He assured that initial production runs were prudent, ensuring sufficient supply for the entire calendar year and beyond, with API and componentry stateside to allow for scaling even if demand exceeds the most optimistic forecasts.

Ed Wu asked about the resolution of weather-related supply issues for Exxua and the company's capacity to ramp up supply if demand increases faster than anticipated.

Answer

CEO Josh Disbrow confirmed that weather-related supply delays, which were minor (a few days), have been corrected, and the supply channels are now clear and adequate. He assured that the company has ample supply to meet demand, even if it outstrips optimistic forecasts, due to prudent initial production runs, stateside API, and componentry for multiples of current production.

Ed Wu requested clarification on Aytu BioPharma's pro forma operating expenses of $39 million and the planned distribution of the $10 million additional investment for the Exua launch throughout the fiscal year.

Answer

CFO Ryan Selhorn clarified that the pro forma annual operating expense is about $36.3 million, with the $10 million Exua launch investment starting in the December quarter (Q2 fiscal 2026). He estimated that approximately 50% of this investment would be spent in Q2, with the remaining 50% distributed across Q3 and Q4, primarily covering sales representatives and marketing materials.

Ed Wu inquired about the possibility of another interim data analysis for the CALMA trial, the rationale behind the recent divestment of a business unit, and plans for seeking Canadian approval for IGC 81 in parallel with FDA approval.

Answer

Ram Mukunda, CEO of IGC Pharma, stated that no further interim data analysis is expected, with the focus now on the final readout. He clarified that the company divested its non-core Vancouver manufacturing facility, not the white label business, to eliminate $600,000 in annual operating expenses, redirect resources to the CALMA trial and other assets, and secure long-term preferential supply rights for the white label business, along with a 10% contingent share of future sale proceeds for the facility. Regarding Canadian approval, Mr. Mukunda confirmed the plan is to seek approval in both the U.S. and Canada, as Health Canada has already approved the trial.

Ed Wu asked about Quantum Computing Inc.'s international opportunities, noting the current focus appears to be primarily in the U.S., and inquired about plans for international expansion.

Answer

Yuping Huang, Interim CEO and Chairman, confirmed active pursuit of international opportunities. He cited examples such as selling the EmuCore system and a vibrometer to TU Delft in Europe, working with a distributor in South Korea, and having Dirac-3 users from Singapore, demonstrating existing international engagement.

Ed Wu from Ascendiant Capital inquired about Quantum Computing Inc.'s plans for international opportunities, noting the current primary focus on the U.S. market.

Answer

Interim CEO and Chairman Yuping Huang confirmed active engagement in international markets, citing the sale of their IMICO system and vibrometer to TU Delft in Europe, work with a South Korean distributor, and Direct3 users from Singapore.